Company intelligence / Profile preview

Acepodia

Grand Cayman, Grand Cayman, Cayman Islandsacepodia.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Acepodia has multiple programs in clinical development. ACE1831 (targeting CD20) is in Phase 1 for non-Hodgkin's lymphoma and is being evaluated for IgG4-related disease. ACE2016 (targeting EGFR) is in Phase 1 for solid tumors. ACE1702 (targeting HER2) has shown safety and tolerability in Phase 1 for HER2-positive tumors.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapiesAntibody-Cell ConjugatesNatural Killer Cell Therapiesγ-δT cell therapiesAntibody-Dual-Drugs Conjugation (AD2C)
Industry: Biotech

Drug pipeline

10 assets

ACE1831

9 more assets in the full pipeline.

Request access →

Partnerships

Pfizer Inc. (strategic clinical collaboration for autoimmune diseases)

Beyond the preview

Go deeper on Acepodia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acepodia.

Explore the full profile